CureVac NV (WBO:CVAC) Net Margin % : -295.34% (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. CureVac NV's Net Income for the three months ended in Sep. 2023 was €-48.68 Mil. CureVac NV's Revenue for the three months ended in Sep. 2023 was €16.48 Mil. Therefore, CureVac NV's net margin for the quarter that ended in Sep. 2023 was -295.34%.

The historical rank and industry rank for CureVac NV's Net Margin % or its related term are showing as below:

WBO:CVAC' s Net Margin % Range Over the Past 10 Years
Min: -704.74 Med: -399.76 Max: -264.21
Current: -704.74

WBO:CVAC's Net Margin % is ranked worse than
68.84% of 1027 companies
in the Biotechnology industry
Industry Median: -162.84 vs WBO:CVAC: -704.74

CureVac NV Net Margin % Historical Data

The historical data trend for CureVac NV's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Net Margin % Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Net Margin %

-553.50

-573.46

-264.21

-399.76

-369.37

CureVac NV Quarterly Data
	Dec18	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Net Margin %	Get a 7-Day Free Trial														-424.25	-1,101.75	-805.43	-889.48	-295.34

Competitive Comparison of CureVac NV's Net Margin %

For the Biotechnology subindustry, CureVac NV's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CureVac NV's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's Net Margin % distribution charts can be found below:

* The bar in red indicates where CureVac NV's Net Margin % falls into.

CureVac NV Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

CureVac NV's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-249.029	/	67.42
	=	-369.37 %

CureVac NV's Net Margin for the quarter that ended in Sep. 2023 is calculated as

Net Margin	=	Net Income (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-48.681	/	16.483
	=	-295.34 %

CureVac NV (WBO:CVAC) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

CureVac NV Net Margin % Related Terms

Thank you for viewing the detailed overview of CureVac NV's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (WBO:CVAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

CVAC:USA CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.